InVivo’s worldwide patent license, co-owned by the Massachusetts Institute of Technology and Harvard’s Children’s Hospital, previously covered a wide range of biopolymers to treat spinal cord injury and to promote the survival and proliferation of cells in the spinal cord.

The license includes 10 issued US patents and 3 pending US patents as well as 67 international patents and 34 pending international patents.

InVivo will leverage its experience in spinal cord injury to create new treatment options for peripheral nerve injuries, epidural injections, cavernous nerve repair following prostate surgery, retina repair, spinal cord tumors, and for applications in the brain.